Our Science and Pipeline

Science
Pipeline

Latest news

May 12, 2026

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

Read more
May 07, 2026

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

Read more
May 04, 2026

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

Read more

More news

Back to Top
X